Compounds > n-methylisoindigotin
Page last updated: 2024-12-07

n-methylisoindigotin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-methylisoindigotin: used in therapy of Lewis lung carcinoma; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID126274
CHEMBL ID607535
SCHEMBL ID13299737
SCHEMBL ID130855
SCHEMBL ID24186711
MeSH IDM0136757

Synonyms (52)

Synonym
HMS1593P16
OPREA1_162254
1-methyl-3,3'-biindolenyl-2,2'-dione
biindolene deriv.
(3e)-1-methyl-3-(2-oxoindolin-3-ylidene)indolin-2-one
n-methylisoindigotin
AKOS000360184
CHEMBL607535
meisoindigo
(3e)-1-methyl-3-(2-oxo-1h-indol-3-ylidene)indol-2-one
97207-47-1
92uip6405r ,
dian iii
2h-indol-2-one, 3-(1,2-dihydro-2-oxo-3h-indol-3-ylidene)-1,3-dihydro-1-methyl-
unii-92uip6405r
S5327
SCHEMBL13299737
HY-13680
SCHEMBL130855
methylisoindigotin
(e)-1-methyl-[3,3'-biindolinylidene]-2,2'-dione
natura-.alpha.
meisoindigo [who-dd]
tak-114
EX-A361
natura-a
AC-8412
1-methyl-3-(2-oxo-2,3-dihydro-1h-indol-3-ylidene)-2,3-dihydro-1h-indol-2-one
1416052-36-2
mfcd05988503
AS-73456
(e)-1-methyl-1h,1'h,2h,2'h-[3,3'-biindolylidene]-2,2'-dione
sr-01000274672
SR-01000274672-1
1-methyl-3,3'-biindole-2,2'(1h,1'h)dione
3-(2-hydroxy-1-methylindol-3-yl)indol-2-one
AKOS032947341
1-methyl-[3,3'-biindolinylidene]-2,2'-dione
3-(1,2-dihydro-2-oxo-3h-indol-3-ylidene)-1,3-dihydro-1-methyl-2h-indol-2-one
dian iii;n-methylisoindigotin;natura-alpha
A13841
SB16469
2h-indol-2-one,3-(1,2-dihydro-2-oxo-3h-indol-3-ylidene)-1,3-dihydro-1-methyl-
(e)-1,1'-dimethyl-[3,3'-biindolinylidene]-2,2'-dione
CCG-267207
Q27271531
dian iii;n-methylisoindigotin;natura-
DTXSID901025868
SCHEMBL24186711
M3082
1-methyl-[3,3 inverted exclamation mark -biindolinylidene]-2,2 inverted exclamation mark -dione
SY235006

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The profiles of plasma concentration versus time were plotted and the relevant pharmacokinetic parameters were calculated for meisoindigo and its reductive metabolites."( Evaluation of meisoindigo, an indirubin derivative: in vitro antileukemic activity and in vivo pharmacokinetics.
Ho, PC; Huang, M; Lee, YS; Lin, HS, 2014)		0.4

Dosage Studied

ExcerptRelevanceReference
"Multiple methods, including dose-response curve, trypan blue exclusion, cytomorphology, DNA electrophoresis, flow cytometry and TUNEL (TdT mediated dUTP nick and labeling), were used to observe the effect of meisoindigo on K562 cells."( [Apoptosis inducing effect of meisoindigo on K562 cells].
Qian, L; Song, L, 1999)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (108)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID453538Inhibition of PLK1 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453336Inhibition of FGFR3 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453309Inhibition of AKT1 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453534Inhibition of PIM1 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453533Inhibition of PIK3CG at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453550Inhibition of TGFBR1 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453529Inhibition of PDGFRB at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453326Inhibition of CSNK1G2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453546Inhibition of RPS6KA3 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453523Inhibition of p38beta at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453325Inhibition of CSNK1D at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453554Inhibition of TYK2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID1161261Induction of cell cycle arrest in human K562 cells assessed as accumulation at S phase at 10 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 44.90%)2014European journal of medicinal chemistry, Oct-30, Volume: 86Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
AID453312Inhibition of AURKA at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID1161251Cytotoxicity against human HeLa cells after 48 hrs by SRB assay2014European journal of medicinal chemistry, Oct-30, Volume: 86Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
AID453339Inhibition of IGF1R at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453555Inhibition of ULK2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453317Inhibition of BTK at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453553Inhibition of TSSK1B at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453335Inhibition of FGFR2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453345Inhibition of JNK1 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453552Inhibition of TRKA at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453348Inhibition of KIT at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453302Antiproliferative activity against human HL60 cells after 5 days by MTT assay2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453328Inhibition of DYRK1B at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453315Inhibition of BMPR2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453541Inhibition of PRKCE at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453513Inhibition of MAP3K4 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453333Inhibition of ERK1 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453518Inhibition of MET at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453343Inhibition of JAK2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453338Inhibition of GSK3-beta at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453332Inhibition of ERBB4 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453520Inhibition of MKNK2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453330Inhibition of EPHA2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453559Inhibition of CDK2/cyclin A at 10 uM by IMAP assay2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453521Inhibition of MLK2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453301Antiproliferative activity against human K562 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453305Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453532Inhibition of PIK3CA at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453327Inhibition of DCAMKL1 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453316Inhibition of BRAF at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453310Inhibition of AKT2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453344Inhibition of JAK3 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID1161246Cytotoxicity against human K562 cells after 48 hrs by SRB assay2014European journal of medicinal chemistry, Oct-30, Volume: 86Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
AID453512Inhibition of LKB1 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453536Inhibition of PIM3 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453313Inhibition of AURKB at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453324Inhibition of CSF1R at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453539Inhibition of PLK3 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453331Inhibition of ERBB2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453549Inhibition of SRPK3 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453514Inhibition of MAPKAPK2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453545Inhibition of ROCK2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453527Inhibition of PCTK1 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID1161252Cytotoxicity against human VEC cells after 48 hrs by SRB assay2014European journal of medicinal chemistry, Oct-30, Volume: 86Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
AID453308Inhibition of ADCK3 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453303Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453544Inhibition of RIOK2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453346Inhibition of JNK2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID1161249Cytotoxicity against mouse L1210 cells after 48 hrs by SRB assay2014European journal of medicinal chemistry, Oct-30, Volume: 86Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
AID453323Inhibition of CHEK1 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453540Inhibition of PLK4 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID1161259Induction of cell cycle arrest in human K562 cells assessed as accumulation at G0/G1 phase at 10 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 36.14%)2014European journal of medicinal chemistry, Oct-30, Volume: 86Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
AID453516Inhibition of MEK1 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453556Inhibition of VEGFR2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453322Inhibition of CDK9 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453306Inhibition of ABL1 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453320Inhibition of CDK3 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453524Inhibition of PAK1 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453311Inhibition of ALK at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453314Inhibition of AXL at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453307Inhibition of ACVR1B at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453329Inhibition of EGFR at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453530Inhibition of PDPK1 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID1161260Induction of cell cycle arrest in human K562 cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 18.96%)2014European journal of medicinal chemistry, Oct-30, Volume: 86Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
AID453304Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453525Inhibition of PAK2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453543Inhibition of RET at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453519Inhibition of MKNK1 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453522Inhibition of p38alpha at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453551Inhibition of TIE2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID1161247Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay2014European journal of medicinal chemistry, Oct-30, Volume: 86Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
AID453319Inhibition of CDK2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453547Inhibition of SNARK at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453535Inhibition of PIM2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453531Inhibition of PIK3C2B at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453321Inhibition of CDK7 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID1161250Cytotoxicity against human A549 cells after 48 hrs by SRB assay2014European journal of medicinal chemistry, Oct-30, Volume: 86Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
AID453337Inhibition of FLT3 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453528Inhibition of PDGFRA at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453517Inhibition of MEK2 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453341Inhibition of IKK-beta at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453548Inhibition of SRC at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453334Inhibition of FAK at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453347Inhibition of JNK3 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453557Inhibition of YANK3 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453318Inhibition of CDK11 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453558Inhibition of ZAP70 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID1161248Cytotoxicity against human MGC803 cells after 48 hrs by SRB assay2014European journal of medicinal chemistry, Oct-30, Volume: 86Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
AID453340Inhibition of IKKalpha at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453542Inhibition of RAF1 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453526Inhibition of PAK4 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453537Inhibition of PKACalpha at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453342Inhibition of INSR at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
AID453515Inhibition of MARK3 at 10 uM2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (5.88)18.7374
1990's4 (11.76)18.2507
2000's11 (32.35)29.6817
2010's14 (41.18)24.3611
2020's3 (8.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.42 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.94%)6.00%
Case Studies1 (2.94%)4.05%
Observational0 (0.00%)0.25%
Other32 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
hydroxyurea
[no description available]		3.5120one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
indirubin-3'-monoxime
indirubin-3'-monoxime: has antiangiogenic activity. indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.		2.0510
thymidine
[no description available]		1.9610pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
uridine
[no description available]		1.9610uridinesdrug metabolite;
fundamental metabolite;
human metabolite
indirubin
[no description available]		4.250
deoxycytidine
[no description available]		2.1310pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		2.1310organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
pyrrolidine dithiocarbamate
pyrrolidine dithiocarbamic acid: spelled pyrolidine in J Nutr 1979 reference; RN given refers to parent cpd. pyrrolidine dithiocarbamate : A member of the class of dithiocarbamic acids that is the N-dithiocarboxy derivative of pyrrolidine.		2.2510dithiocarbamic acids;
pyrrolidines		anticonvulsant;
antineoplastic agent;
geroprotector;
neuroprotective agent;
NF-kappaB inhibitor;
radical scavenger
imatinib mesylate
imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.		2.0510methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
isoindigotin
isoindigotin: used in treatment of chronic granulocytic leukemia; structure given in first source		2.4620
6-bromoindirubin-3'-oxime
6-bromoindirubin-3'-oxime: structure in first source. 6-bromoindirubin-3'-oxime : A member of the class of biindoles that is indirubin substituted at position 6 by a bromo group and in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.		2.0510
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		2.0210
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Bowel Diseases, Inflammatory
[description not available]		02.3110
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		02.3110
Inflammatory Bowel Diseases
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.		02.3110
Alloxan Diabetes
[description not available]		02.2510
Diabetes Mellitus, Adult-Onset
[description not available]		02.2510
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.2510
Diabetic Cardiomyopathies
Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.		02.2510
Astrocytoma, Grade IV
[description not available]		02.3110
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		02.3110
Palmoplantaris Pustulosis
[description not available]		02.0810
Psoriasis
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.		02.0810
Leucocythaemia
[description not available]		02.110
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		02.110
Cancer of Pancreas
[description not available]		03.0440
Carcinoma, Ductal, Pancreatic
[description not available]		02.1310
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		03.0440
Carcinoma, Pancreatic Ductal
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.		02.1310
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.1510
Innate Inflammatory Response
[description not available]		02.1510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.1510
Colorectal Cancer
[description not available]		02.0410
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.0410
Minimal Disease, Residual
[description not available]		02.0510
Ph 1 Chromosome
[description not available]		02.0510
Granulocytic Leukemia, Chronic
[description not available]		03.8540
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.		03.8540
Acute Myelogenous Leukemia
[description not available]		02.0510
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		02.0510
Blast Phase
[description not available]		02.9210
Blast Crisis
An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.		02.9210
Granulocytic Leukemia
[description not available]		01.9910
Leukemia, Myeloid
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.		01.9910
Carcinoma 256, Walker
A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)		01.9610
Leukemia L 1210
[description not available]		01.9610
Cancer of Lung
[description not available]		01.9610
Experimental Neoplasms
[description not available]		01.9610
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9610